ICER Gives NASH Drug Resmetirom High Marks, Obeticholic Acid Not So MuchFebruary 20th 2023
At a placeholder price of $19,000, resmetirom would produce cost savings, says the drug evaluation group. Obeticholic acid’s price would need to be slashed to meet a commonly used cost-effectiveness threshold.
Mark Cuban Assails PBMs at AAM meetingFebruary 18th 2023
Cuban, of "Shark Tank' fame and owner of the Dallas Mavericks, called drugs prices ‘insane’ and used some profanity when talking pharmacy benefit managers at the annual meeting of the Association for Accessible Medicines yesterday. Cuban has co-founded an online pharmacy that he says will make drug prices lower and transparent.
Researchers: Ancillary Services Would Comprise 20% of Medicare Spending on AduhelmJanuary 15th 2022
In a research letter published in JAMA Health Forum, researchers say most of the cost figures for Aduhelm have left out the additional MRI scans and other services that will be required because the drug is associated with the development of amyloid-related imaging abnormalities (ARIAs).